Wednesday, January 30, 2019

n $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s, Friedreich’s Ataxia

Neurocrine Biosciences will partner with Voyager Therapeutics to develop and commercialize its gene therapy programs for Parkinson’s disease and Friedreich’s ataxia, plus two other programs to be determined, through a collaboration that could generate more than $1.865 billion for Voyager, the companies said today.



https://www.equities.com/news/voyager-therapeutics-signs-deal-with-neurocrine-for-parkinson-s-disease-and-friedrich-s-ataxia

https://www.genengnews.com/news/in-1-9b-alliance-neurocrine-to-develop-voyager-gene-therapies-for-parkinsons-friedreichs-ataxia/

https://www.bioportfolio.com/news/article/3884104/In-1-9B-Alliance-Neurocrine-to-Develop-Voyager-Gene-Therapies-for-Parkinsons.html

https://www.bioportfolio.com/news/article/3884136/In-1-9B-Alliance-Neurocrine-NBIX-to-Develop-Voyager-VYGR-Gene-Therapies.html

http://www.rttnews.com/story.aspx?Id=2973652

https://finance.yahoo.com/news/neurocrine-biosciences-voyager-therapeutics-form-120000722.html

https://globenewswire.com/news-release/2019/01/29/1706690/0/en/Neurocrine-Biosciences-and-Voyager-Therapeutics-Form-Strategic-Development-and-Commercialization-Collaboration-for-Parkinson-s-Disease-and-Friedreich-s-Ataxia.html

https://www.biospace.com/article/neurocrine-and-voyager-team-up-on-huge-deal-for-gene-therapy-treatment-for-parkinson-s-disease/